Answers are grounded in this paper and cite their sources.
Clinical trial reveals baseline monocyte counts predict treatment responses in chronic spontaneous urticaria, suggesting monocytes serve as a practical biomarker for therapy efficacy.
Background Chronic spontaneous urticaria (CSU) is a relapsing, immune‐mediated skin disease. However, the role of monocytes in its pathogenesis and clinical significance remains unclear. Objective This study aimed to investigate the correlation between peripheral blood monocyte counts and clinical features in CSU patients, as well as to explore their potential predictive value for the therapeutic efficacy of second‐generation H1‐antihistamines (sgAHs) and omalizumab. Methods Two independent patient cohorts were included: Cohort 1 was utilized to evaluate sgAHs treatment efficacy, while Cohort 2 was employed to analyze omalizumab efficacy in CSU patients. Results A total of 656 and 105 CSU patients were enrolled in Cohort 1 and Cohort 2, respectively. Baseline peripheral blood monocyte levels were significantly associated with treatment outcome in both cohorts (OR = 0.005, p < 0.001; OR = 0.07, p = 0.005, respectively). Furthermore, compared to baseline levels, peripheral blood monocyte counts decreased significantly in both cohorts ( p < 0.0001 and p = 0.0205, respectively). In Cohort 2, fast‐responders, but not slow‐responders or non‐responders, exhibited a significantly greater reduction in monocyte counts post‐treatment ( p = 0.0031 for fast‐responders, p = 0.5285 for slow‐responders, and p = 0.7565 for non‐responders, respectively). Conclusion Baseline monocyte counts were significantly correlated with the therapeutic efficacy of both sgAHs and omalizumab in CSU patients. Trial Registration: Chinese Clinical Trial Registry: ChiCTR‐OCH‐14004518
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: